Evidence map›Paper›PMID 41491993›Full record

ArticleMolecular neurodegeneration2026

OMG! A proteomic determinant of neurodegenerative resiliency.

Michael R Duggan, Hamilton Se-Hwee Oh, Philipp Frank, Gabriela T Gomez, David Zweibaum, Yuhan Cui, Jingsha Chen, Aditya Surapaneni, Cassandra O Blew, Heather E Dark and 46 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular neurodegeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Proteomic Signatures of ProtectedmedRxiv : the preprint server for health sciences · 2026
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

56 authors.

Michael R DugganLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH BRC BG RM 04B311, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
Hamilton Se-Hwee OhGraduate Program in Stem Cell and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Philipp FrankDepartment of Epidemiology and Public Health, University College London, London, UK.
Gabriela T GomezDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
David ZweibaumTranslational Gerontology Branch, National Institute on Aging, Baltimore, MD, USA.
Yuhan CuiArtificial Intelligence in Biomedical Imaging Laboratory, Perelman School of Medicine, Philadelphia, PA, USA.
Jingsha ChenDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Aditya SurapaneniDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Cassandra O BlewLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH BRC BG RM 04B311, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
Heather E DarkLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH BRC BG RM 04B311, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
Cassandra M JoynesLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH BRC BG RM 04B311, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
Sridhar KandalaLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH BRC BG RM 04B311, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
Murat BilgelLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH BRC BG RM 04B311, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
Amelia FarinasThe Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, CA, USA.
Guray ErusArtificial Intelligence in Biomedical Imaging Laboratory, Perelman School of Medicine, Philadelphia, PA, USA.
Qu TianTranslational Gerontology Branch, National Institute on Aging, Baltimore, MD, USA.
Julián CandiaTranslational Gerontology Branch, National Institute on Aging, Baltimore, MD, USA.
Krishna A PuchaLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Bennett A LandmanDepartment of Radiology & Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.
Logan DumitrescuVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Timothy J HohmanVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Alexandria LewisDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abhay MoghekarDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fatemeh SiavoshiDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Muhammad AliDepartment of Psychiatry, Washington University, St. Louis, MO, USA.
Menghan LiuDepartment of Psychiatry, Washington University, St. Louis, MO, USA.
Ying XuDepartment of Psychiatry, Washington University, St. Louis, MO, USA.
Daniel WesternDepartment of Psychiatry, Washington University, St. Louis, MO, USA.
Naoto KanekoNEC Solution Innovators Limited, Koto-ku, Tokyo, Japan.
Shintaro KatoNEC Solution Innovators Limited, Koto-ku, Tokyo, Japan.
Makio FuruichiNEC Solution Innovators Limited, Koto-ku, Tokyo, Japan.
Masaki ShibayamaNEC Solution Innovators Limited, Koto-ku, Tokyo, Japan.
Masahisa KatsunoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Yukiko NishitaDepartment of Epidemiology of Aging, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Rei OtsukaDepartment of Epidemiology of Aging, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Rebecca F GottesmanStroke Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Eric B DammerDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA.
Nicholas T SeyfriedDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA.
Allan I LeveyGoizueta Brain Health Institute and Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Erik C B JohnsonGoizueta Brain Health Institute and Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Elizabeth MorminoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Anthony D WagnerWu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.
Kathleen L PostonThe Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, CA, USA.
Dimitrios KapogiannisLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Morgan E GramsDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Pavan BhargavaDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Iwao WagaNEC Solution Innovators Limited, Koto-ku, Tokyo, Japan.
Christos DavatzikosArtificial Intelligence in Biomedical Imaging Laboratory, Perelman School of Medicine, Philadelphia, PA, USA.
Susan M ResnickLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH BRC BG RM 04B311, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
Luigi FerrucciTranslational Gerontology Branch, National Institute on Aging, Baltimore, MD, USA.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University, St. Louis, MO, USA.
Tony Wyss-CorayThe Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, CA, USA.
Mika KivimäkiBrain Sciences, University College London, London, UK.
Josef CoreshDepartment of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Keenan A WalkerLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH BRC BG RM 04B311, 251 Bayview Blvd, Baltimore, MD, 21224, USA. keenan.walker@nih.gov.

Funding

THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2022 to 2025
$5.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2022 to 2025
$5.0M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00004 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WINDHAM, BEVERLY GWEN · 2022 to 2025
$4.8M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00002 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2022 to 2025
$4.7M
NHLBI NIH HHS 75N92022D00001NHLBI NIH HHS 75N92022D00002NHLBI NIH HHS 75N92022D00003NHLBI NIH HHS 75N92022D00004NHLBI NIH HHS 75N92022D00005
6 · The paper itself

Abstract

backgroundBiofluid proteomics can enhance our understanding of the neurodegenerative mechanisms underlying Alzheimer's disease and related dementias (ADRDs). Oligodendrocyte myelin glycoprotein (OMG) is a brain-specific protein implicated in myelination, but its potential mechanistic, biomarker, and therapeutic roles in ADRDs requires further elucidation.

methodsAfter detecting an inverse association between its abundance in peripheral circulation and cortical amyloid deposition in two community-based cohorts, the current study characterized OMG's role in ADRDs with high-throughput proteomics from sixteen independent cohorts. Data included a variety of cross-sectional and longitudinal community-based and clinical cohorts from North America, Europe, and Asia, and incorporated complementary biofluids, biospecimens, and proteomic platforms. Statistical analyses were conducted separately in each cohort.

resultsWe detected lower plasma OMG in individuals with cortical amyloid deposition, compromised brain structure, dementia, and multiple sclerosis, as well as in individuals who developed dementia over 7- to 20-year follow-up periods. OMG's CSF and brain proteomic signatures reflected broader neuroprotective mechanisms, especially axonal structural integrity, and two-sample Mendelian randomization causally implicated OMG as protective against multiple neurodegenerative diseases.

conclusionsOur findings implicate OMG as a mechanistic determinant of neurodegenerative resiliency among older adults, which is reliably captured by its abundance in peripheral circulation.

Indexed as

Alzheimer DiseaseDementiaNeurodegenerative DiseasesAgedBiomarkersBrainCohort StudiesCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedProteomicsBiomarkers

Identifiers

PMID41491993
PMCPMC12870269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.